Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a Healthcare company (Medical - Devices) with a market capitalization of $1.2B. The Maz Rating grades it against the other companies in its sector.
Tandem Diabetes Care, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $17.06, Tandem Diabetes Care, Inc. trades at 1.1x sales and 8.9x book value. Over the last twelve months it generated about $1.1B of revenue and a net loss of $50M. It runs a gross margin of 56.6%, an operating margin of -2.4% and a net margin of -4.6%. It shows return on equity of -35.6%, return on invested capital of -2.7% and a free cash flow yield of -3.0%. On the balance sheet: a debt-to-equity ratio of 5.45 and a current ratio of 3.21. Over the past 52 weeks the share price ranged from $12.26 to $29.65, with a beta of 1.59.
Tandem Diabetes Care, Inc. does not currently pay a dividend.
39 Wall Street analyst ratings cover the stock: 23 Buy and 16 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.